article
An overview of Alzheimer’s disease drug targets
Alzheimer’s disease (AD) is the most common form of dementia which typically occurs after the age of 65 and is characterised by progressive cognitive impairment...
List view / Grid view
Drug Discovery
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
news
Drug discovery crisis linked to bad technology choices
15 February 2016 | By Victoria White
Researchers say drug discovery processes are becoming unsustainably expensive despite huge technological advances because the wrong methods are being used…
article
The relevance of homogeneous radiometric assays in modern drug discovery
In the past two decades, several alternative, non-radiometric assay formats have been developed for the high-throughput screening (HTS) of target classes such as protein kinases, which were previously screened using radiometric assays. Radiometric screening (and the expertise to perform such HTS) has thus declined in recent years...
article
Finding a cure for neglected tropical diseases with cell-based assays
Neglected tropical diseases pose a significant threat to public health and affect nearly one billion people in tropical and sub-tropical regions throughout the world. There is a pressing need to identify new therapeutics for NTDs and many developed nations are participating in drug discovery efforts...
article
canSAR: a portal to Big Data for drug discovery
9 February 2016 | By Dr Bissan Al-Lazikani and Elizabeth Coker, The Institute of Cancer Research, London
Dr Bissan Al-Lazikani and Elizabeth Coker discuss canSAR: the first public domain example of Big Data for drug discovery...
news
ADDoPT project set to transform the UK pharma industry
28 January 2016 | By Victoria White
The ADDoPT project addresses the key challenge of getting new innovative medicines to market in the quickest and most cost-effective way...
news
Neurodegenerative diseases: The potential of cyclophilin inhibition
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
news
LDC enters new drug discovery partnership with Roche
21 January 2016 | By Victoria White
The Lead Discovery Centre (LDC) and Roche have announced that they are to collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need...
news
PDi launched to enhance translation of phenotypic biology to novel therapeutics
20 January 2016 | By Victoria White
Through the Phenotypic Discovery Initiative (PDi), partners will build robust, disease-relevant phenotypic assays with a focus on human-derived systems with the aim of identifying new drug targets and hit molecules.
news
Time to renew the antibiotic arsenal
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
news
Breast cancer study reveals new drug targets and combinations
19 January 2016 | By Victoria White
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
news
Centauri acquires Alphamer technology from Altermune
18 January 2016 | By Victoria White
Centuari has also announced that it has appointed Dr Clive Dix as Chairman and secured the first tranche of a £3M raise to develop its first lead candidate...
news
Registration has now opened for Oxford Global’s 17th Annual Drug Discovery Leaders Summit
13 January 2016 | By Oxford Global
Oxford Global Conferences are proud to present the successful 17th Annual Drug Discovery Leaders Summit and co-located 4th Annual Discovery Chemistry & Drug Design Congress taking place on the 13th & 14th June in Berlin...
news
Boehringer and Arena to advance research in psychiatric diseases
13 January 2016 | By Victoria White
Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates for psychiatric diseases...
news
MSD acquires drug discovery company IOmet
12 January 2016 | By Victoria White
The acquisition includes IOmet's comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors...
